• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: lorlatinib
Trade Name: Lorbrena
Date Designated: 06/23/2015
Orphan Designation: Treatment of anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer
Orphan Designation Status: Designated/Approved
Pfizer, Inc.
235 East 42nd Street
New York, New York 10017
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: lorlatinib
Trade Name: Lorbrena
Marketing Approval Date: 11/02/2018
Approved Labeled Indication: LORBRENA® is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or alectinib as the first ALK inhibitor therapy for metastatic disease; or ceritinib as the first ALK inhibitor therapy for metastatic disease.
Exclusivity End Date: 11/02/2025 
Exclusivity Protected Indication* :  LORBRENA® is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or alectinib as the first ALK inhibitor therapy for metastatic disease; or ceritinib as the first ALK inhibitor therapy for metastatic disease.
2 Generic Name: lorlatinib
Trade Name: Lorbrena
Marketing Approval Date: 03/03/2021
Approved Labeled Indication: treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
Exclusivity End Date: 03/03/2028 
Exclusivity Protected Indication* :  Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test, excluding patients whose disease has progressed on crizotinib and at least one other ALK inhibitor; or alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

*Exclusivity Protected Indications are shown for approvals from Jan. 1, 2013, to the present.
-
-